Drug Profile
Research programme: anti-inflammatory therapeutics - Yuhan
Alternative Names: YH-Chem2; YH-NCE1Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Yuhan
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Asthma in South Korea
- 01 Apr 2019 Preclinical trials in Asthma in South Korea before April 2019 (Yuhan Corporation pipeline, April 2019)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in South Korea